| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 20
| Issue : 1 | Page : 55-59 |
|
|
Ketamine in treatment-resistant depression: A review of completed investigations
Shweta S Verma M.D.
Department of Behavioral Health, Kaiser Permanente, Mid-Atlantic Permanente Medical Group, USA
Correspondence Address:
Shweta S Verma
Kaiser Permanente Behavioral Health, 5999 Burke Commons Road, Burke, VA 22015
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-9903.151741
|
|
|
Background and Objective: The objective was to evaluate clinical trial data on the use of ketamine in treating treatment-resistant depression (TRD). Materials and Methods: PubMed search (November 2012) was initiated using the keywords: Ketamine, resistant depression. Inclusion criterion included: English language publications describing clinical trial reports on humans with TRD. Results: A total of 360 patients across 15 clinical trials with TRD were treated with infusional ketamine. On average 15-90% of patients reported a >50% decrease in their baseline Montgomery-Åsberg Depression Rating Scale/Hamilton Rating Scale for Depression scores at 4 h. Response rates decreased significantly as time progressed. Conclusion: Infusional ketamine has a significant rapid, short-term antidepressant effect in the treatment of TRD. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
